NUEVOLUTION A/S
Core data
Name | NUEVOLUTION A/S |
Address | Rønnegade 8 5, 2100, København Ø |
Founded | May 8, 2001 |
Employees | 101 |
Locations (P-units) | 2View locations |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | NUEVOLUTION A/S |
Address | Rønnegade 8 5, 2100, København Ø |
Founded | May 8, 2001 |
Employees | 101 |
Locations (P-units) | 2View locations |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of NUEVOLUTION A/S
Description
Company and research and development activitiesNuevolution A/S is a Danish biopharmaceutical company focused on developing drug treatments for human disease within oncology, inflammatory diseases and cardiometabolic diseases.Nuevolution A/S is the inventor of Chemetics, a drug discovery platform, which enables efficient discovery of novel small molecule (tablet based) drug candidates.The Chemetics platform provides access to screening of trillions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate.Our efforts are leveraged by a proven and highly efficient drug discovery engine, and backed by a skilled and dedicated team of employees, world-class academic and corporate expert advisers catalyzing our ambition to deliver new medicines to patients.
Financials
| Reporting period | 2025DKK | |||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 203,323,000 | |||||||
| Operating profit | 44,773,000 | |||||||
| Profit before tax | 40,251,000 | |||||||
| Net income | 39,754,000 | |||||||
| Total assets | 238,040,000 | |||||||
| Equity | 89,493,000 | |||||||
| Avg. employees | 80 | |||||||
2018–2025 Unlock financial history | ||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
No contact details have been registered for this company.
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Tore von Würden Petersen | Roles Board | TitlesFORMAND |
| Thomas Franch | Roles Management | TitlesDIREKTØR |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| EY Godkendt Revisionspartnerselskab | AuditorHans B. Vistisen | RoleState AuthorisedPublic Accountant | FromJun 29, 2026 |
| EY Godkendt Revisionspartnerselskab | AuditorMads Obel Knøsgaard | RoleState AuthorisedPublic Accountant | FromJun 29, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Foreign legal entity | Ownership100 % | Voting rights100 % | FromNov 15, 2023 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇺🇸Amgen, Inc. | Ownership through Direct | 100 % |